NO20062609L - Farmasoytisk preparat for oral administrering av et pyrazol-3-karboksamidderivat - Google Patents

Farmasoytisk preparat for oral administrering av et pyrazol-3-karboksamidderivat

Info

Publication number
NO20062609L
NO20062609L NO20062609A NO20062609A NO20062609L NO 20062609 L NO20062609 L NO 20062609L NO 20062609 A NO20062609 A NO 20062609A NO 20062609 A NO20062609 A NO 20062609A NO 20062609 L NO20062609 L NO 20062609L
Authority
NO
Norway
Prior art keywords
pyrazole
oral administration
pharmaceutical preparation
carboxamide derivative
derivative
Prior art date
Application number
NO20062609A
Other languages
English (en)
Inventor
Thierry Breul
Jean Claude Gautier
Olivier Saslawski
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20062609L publication Critical patent/NO20062609L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er beskrevet et farmasøytisk preparat i flytende eller halvfast form som er selvemulgerende eller selv-mikroemulgerende i et vandig medium, for oral administrering av et pyrazol-3-karboksamidderivat, hvor nevnte derivat er oppløseliggjort i en amflfll blanding irmeholdende ett eller flere lipide oppløsningsmidler og en ikke-ionisk hydrofll surfaktant
NO20062609A 2003-11-10 2006-06-06 Farmasoytisk preparat for oral administrering av et pyrazol-3-karboksamidderivat NO20062609L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0313259A FR2861992B1 (fr) 2003-11-10 2003-11-10 Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
PCT/FR2004/002875 WO2005046690A1 (fr) 2003-11-10 2004-11-09 Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3­carboxamide

Publications (1)

Publication Number Publication Date
NO20062609L true NO20062609L (no) 2006-06-06

Family

ID=34508418

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062609A NO20062609L (no) 2003-11-10 2006-06-06 Farmasoytisk preparat for oral administrering av et pyrazol-3-karboksamidderivat

Country Status (28)

Country Link
US (2) US20060264469A1 (no)
EP (1) EP1691808B1 (no)
JP (1) JP4767171B2 (no)
KR (1) KR20060108668A (no)
CN (1) CN100528158C (no)
AR (1) AR047237A1 (no)
AT (1) ATE429227T1 (no)
AU (1) AU2004289086A1 (no)
BR (1) BRPI0416341A (no)
CA (1) CA2544413A1 (no)
CY (1) CY1110478T1 (no)
DE (1) DE602004020797D1 (no)
DK (1) DK1691808T3 (no)
ES (1) ES2325373T3 (no)
FR (1) FR2861992B1 (no)
HK (1) HK1102021A1 (no)
HR (1) HRP20090393T1 (no)
IL (1) IL175556A (no)
MA (1) MA28419B1 (no)
NO (1) NO20062609L (no)
NZ (1) NZ547763A (no)
PL (1) PL1691808T3 (no)
PT (1) PT1691808E (no)
RU (1) RU2321404C1 (no)
SI (1) SI1691808T1 (no)
TW (1) TWI280129B (no)
WO (1) WO2005046690A1 (no)
ZA (1) ZA200604451B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
CA2697328C (en) * 2007-08-21 2015-08-11 Basilea Pharmaceutica Ag Antifungal composition
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
WO2012071043A1 (en) * 2010-11-24 2012-05-31 Pharmaceutics International, Inc. Self micro-emulsifying drug delivery system with increased bioavailability

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059691A (en) * 1990-01-22 1991-10-22 American Cyanamid Company N-((dialkylamino)methylene)-substituted pyrazolo (1,5-A)-pyrimidine-3-carboxamides and N-((dialkylamino)methylene)-substituted-4,5-dihydropyrazolo-(1,5-A)-pyrimidine-3-carboxamides
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
SI0649651T1 (en) * 1993-09-28 2001-02-28 Scherer Gmbh R P Soft gelatin capsule manufacture
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
WO1996033697A1 (fr) * 1995-04-24 1996-10-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulation auto-emulsionnable formant une emulsion huile dans l'eau
CA2221145A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
ID23177A (id) * 1997-03-14 2000-03-23 Otsuka Pharma Co Ltd Turunan pirimidin baru
FR2761265B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
US6617426B1 (en) * 1999-06-22 2003-09-09 Merck & Co Inc Cysteinyl protease inhibitors
JP2001151669A (ja) * 1999-11-24 2001-06-05 Nippon Kayaku Co Ltd 経口用自己乳化製剤
CA2395331C (en) * 1999-12-23 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
WO2003074027A2 (en) * 2002-03-01 2003-09-12 Novagali Pharma Sa Self emulsifying drug delivery systems for poorly soluble drugs
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process

Also Published As

Publication number Publication date
ES2325373T3 (es) 2009-09-02
NZ547763A (en) 2009-08-28
MA28419B1 (fr) 2007-02-01
WO2005046690A1 (fr) 2005-05-26
EP1691808B1 (fr) 2009-04-22
IL175556A (en) 2010-11-30
FR2861992B1 (fr) 2007-07-20
CN100528158C (zh) 2009-08-19
US20060264469A1 (en) 2006-11-23
BRPI0416341A (pt) 2007-02-27
SI1691808T1 (sl) 2009-10-31
HK1102021A1 (en) 2007-11-02
CN1925856A (zh) 2007-03-07
DE602004020797D1 (de) 2009-06-04
RU2321404C1 (ru) 2008-04-10
HRP20090393T1 (en) 2009-08-31
FR2861992A1 (fr) 2005-05-13
ZA200604451B (en) 2007-10-31
PT1691808E (pt) 2009-07-14
DK1691808T3 (da) 2009-08-03
AU2004289086A1 (en) 2005-05-26
RU2006120447A (ru) 2007-12-20
PL1691808T3 (pl) 2009-09-30
TWI280129B (en) 2007-05-01
US20090004261A1 (en) 2009-01-01
CA2544413A1 (fr) 2005-05-26
TW200524597A (en) 2005-08-01
EP1691808A1 (fr) 2006-08-23
AR047237A1 (es) 2006-01-11
CY1110478T1 (el) 2015-04-29
KR20060108668A (ko) 2006-10-18
JP2007516960A (ja) 2007-06-28
JP4767171B2 (ja) 2011-09-07
IL175556A0 (en) 2008-04-13
ATE429227T1 (de) 2009-05-15

Similar Documents

Publication Publication Date Title
NO20062609L (no) Farmasoytisk preparat for oral administrering av et pyrazol-3-karboksamidderivat
US20220151972A1 (en) Cannabinoid acid ester compositions and uses thereof
NO20070354L (no) Galeniske anvendelser om selvemulgerende blandinger av lipideksipienter
US20080317679A1 (en) Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
NO20073224L (no) Flytende og halvfaste farmasoytiske preparater for oral administrering av et substituert amid
CY1116372T1 (el) Φαρμακευτικα σκευασματα που περιεχουν μεθυλναλτρεξονη
NO20076288L (no) Farmasoytiske sammensetninger innbefattende imatinib og et frigivningssinkende middel
LU92233I2 (fr) Sativex et ses dérivés pharmaceutiquement acceptables
Radomska et al. The use of some ingredients for microemulsion preparation containing retinol and its esters
WO2008110872A2 (en) Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
IE970675A1 (en) New Parasiticidal Combination
NO20090346L (no) Pyrazolderivater som inhibitorer av cytokrom P450
MX2012014443A (es) Composiciones oftalmicas para la administracion de ingredientes activos liposolubles.
DK1771155T3 (da) Fremgangsmåde og sammensætning til behandling af rhinitis
NO20061702L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist
Lee Vitamin E acetate as linactant in the pathophysiology of EVALI
NO20060155L (no) Indol-4-sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer
Dargó et al. Corneal-PAMPA: A novel, non-cell-based assay for prediction of corneal drug permeability
Kapitza et al. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model
CL2004001325A1 (es) Una composicion farmaceutica de aerosol que comprende cilesonida solubilizada en un propelente hidrofluorocarbono y un co-solvente, de preferencia etanol, util como antiinflamatorio de las vias aereas.
CO5580741A2 (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1
EP2407158A1 (en) Ph-responsive liposome
CN101951886A (zh) 增强羟甲唑啉的光稳定性
ES2276110T3 (es) Formulacion farmaceutica que incluye un inhibidor de renina no peptidico y un tensioactivo.
ATE374600T1 (de) Pharmazeutische formulierung enthaltend olanzapin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application